Immuneering Corporation
IMRX
$0.10
Change (1 day)
$8.89
Year High
$1.00
Year Low
Categories
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
Immuneering Corporation (IMRX) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | -54,942,858 | 12.01 M | 102.58 M | 89.08 M | |
| 2022 | 12.42 K | -67,795,204 | 12.52 M | 122.37 M | 108.75 M |
| 2021 | 246.04 K | -69,523,209 | 10.72 M | 166.7 M | 152.33 M |
| 2020 | 500.11 K | -36,469,062 | 60.9 M | 38.42 M | 37.73 M |
| 2019 | 209.94 K | 2.83 M | 20.63 M | 14.1 M | 14.06 M |